Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04493333 · ClinicalTrials.gov registry record · Phase 2
Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
A Phase 2 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04493333 is a Phase 2 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 8 participants.
The verdict
NCT04493333, a Phase 2 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this research is to gather information on the safety and effectiveness of Intrarosa®, also known as Dehydroepiandrosterone (DHEA), and prasterone. By doing this study, the investigators hope to learn if Intrarosa® can improve vaginal discomfort. Participants will be assigned to one of two groups. One group will use Intrarosa® once a day. The other group will use Replens™ two times a week.
Interventions
- DRUG Vaginal Dehydroepiandrosterone
- COMBINATION_PRODUCT Vaginal Polycarbophil Moisturizer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2023-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04493333
The ClinicalTrials.gov registry entry for NCT04493333 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vaginal Dehydroepiandrosterone is the first listed.
NCT04493333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04493333 about?
NCT04493333 is a clinical study titled "Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors". The purpose of this research is to gather information on the safety and effectiveness of Intrarosa®, also known as Dehydroepiandrosterone (DHEA), and prasterone. By doing this study, the investigators hope to learn if Intrarosa® can improve vaginal discomfort. Participants will be assigned to one of...
What is the current status of trial NCT04493333?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2021-06-07. Estimated completion is 2023-07-18.
What interventions are being tested in trial NCT04493333?
The interventions under investigation include: Vaginal Dehydroepiandrosterone (DRUG), Vaginal Polycarbophil Moisturizer (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04493333?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.